• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Platelets >Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome
【24h】

Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome

机译：直接作用抗病毒药治疗后血小板胁迫HCV患者血小板的改善及其与结果的关系

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Little is known about evolution of platelet count after treatment with direct-acting antiviral agents (DAAs). The study aimed to evaluate the changes in platelet count after treatment with DAAs among thrombocytopenic patients with HCV-related advanced fibrosis and cirrhosis. A total of 915 chronic HCV patients with advanced fibrosis and cirrhosis who were treated with different DAAs-based regimens were retrospectively enrolled in final analysis. Included patients were those with thrombocytopenia (TCP). Platelet count was recorded at baseline, end of treatment (EOT) and 24-weeks after EOT (SVR24). Changes in platelet count and its relation to SVR were analyzed. The overall SVR24 rate was 98.8%. The platelet count showed statistically significant improvement from baseline to EOT (107 (84-127) x 10(3)/mm(3) vs. 120 (87-153) x 10(3)/mm(3)(P = <0.0001) but remained unchanged thereafter to SVR24. Among responders, the platelet count significantly increased at SVR24 compared to baseline (P = <0.0001) but in relapsers, there was improvement in platelet count that didn't reach statistical significance (P = 0.9). Logistic regression analysis showed that higher Child-Pugh score and more advanced fibrosis at baseline were significant predictors of decreasing of platelet count and development of severe TCP at SVR24. Among thrombocytopenic patients with HCV-related advanced fibrosis and cirrhosis, the platelet count improved after treatment with DAAs regardless to treatment response.
机译：关于直接作用抗病毒药物（DAA）治疗后血小板计数的变化知之甚少。该研究旨在评估丙型肝炎相关晚期纤维化和肝硬化的血小板减少患者接受DAAs治疗后血小板计数的变化。共有915名患有晚期纤维化和肝硬化的慢性丙型肝炎患者采用不同的DAAs方案进行了回顾性纳入最终分析。包括血小板减少症（TCP）患者。在基线检查、治疗结束（EOT）和EOT后24周（SVR24）记录血小板计数。分析血小板计数的变化及其与SVR的关系。总体SVR24率为98.8%。血小板计数显示，从基线检查到EOT（107（84-127）x10（3）/mm（3）与120（87-153）x10（3）/mm（3）相比，在统计学上有显著改善（P=<0.0001），但到SVR24后，血小板计数保持不变。在应答者中，与基线相比，SVR24时的血小板计数显著增加（P=<0.0001），但在复发者中，血小板计数有所改善，但未达到统计学意义（P=0.9）。逻辑回归分析显示，基线检查时较高的Child-Pugh评分和更严重的纤维化是SVR24血小板计数下降和严重TCP发展的显著预测因子。在伴有丙型肝炎相关的晚期纤维化和肝硬化的血小板减少患者中，无论治疗反应如何，经DAAs治疗后血小板计数均有所改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号